Lilly to begin rollout of Tempo® Personalized Diabetes

Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment ...

Related Keywords

United States , American , Kevin Cammack , P Llyabout Welldoc , Eli Lilly , Google , Instagram , Linkedin , Tempo Customer Support Service , Twitter , American Diabetes Association , Lilly United States , Garmin , Bluetooth Sig Inc , Facebook , Dexcom Inc , Apple Health , Drug Administration , Health Outcomes , Exchange Commission , Continuous Glucose Monitoring Systems , Tempo Blood Glucose Monitor , Personalized Diabetes Management Platform , Tempo Smart , Smart Button , Tempo Insights , Connected Care , Tempo Smart Button , Tempo Pen , Dexcom Continuous Glucose Monitoring , European Conformity , Tempo Personalized Diabetes Management , Tempo Personalized Diabetes Management Platform , Tempo Pens , Safety Information , Healthcare Provider , Temposmart App , Tempo Smart Button Instructions , Temposmart App User Guides , Welcome Kit , Tempo Refill Kit , Prescribing Information , Pabout Lilly , Private Securities Litigation Reform Act , United States Securities , Behavior Change , Improve Health Outcomes , Tempo Rings ,